Late-Onset Neutropenia after Rituximab Treatment for Adult-Onset Nephrotic Syndrome
Clicks: 245
ID: 7990
2019
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Steady Performance
70.6
/100
240 views
195 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
A 41-year-old woman developed nephrotic syndrome at the age of 32 and was diagnosed with minimal change nephrotic syndrome based on a renal biopsy. Although remission was achieved with administration of prednisolone (PSL) and cyclosporine, the nephrotic syndrome recurred. She was also started on rituximab (RTX). She developed late-onset neutropenia after RTX treatment (R-LON) and improved 17 days later. Although the majority of R-LON cases undergo spontaneous remission, cases of death have been reported. This report is intended to warn about R-LON, since the use of RTX for adult-onset nephrotic syndrome is expected to increase in the future.
| Reference Key |
mayuko2019lateonsetcase
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Yamazaki, Mayuko;Sugiura, Hidekazu;Iwatani, Yosuke;Kyoda, Mizuki;Nokiba, Hirohiko;Amemiya, Nobuyuki;Nitta, Kosaku;Tsuchiya, Ken;Yamazaki, Mayuko;Sugiura, Hidekazu;Iwatani, Yosuke;Kyoda, Mizuki;Nokiba, Hirohiko;Amemiya, Nobuyuki;Nitta, Kosaku;Tsuchiya, Ken; |
| Journal | case reports in nephrology |
| Year | 2019 |
| DOI |
10.1155/2019/3580941
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.